IACTA Pharmaceuticals is an ophthalmic R&D company developing novel treatments for large eye‑care markets, starting with ocular pain and dry eye disease. Leveraging emerging technologies such as nano‑encapsulation, it accelerates promising research ideas that sit between small research firms and large pharma, turning them into effective eye‑care products. The firm partners with leading pharmaceutical companies to bring these innovations to patients worldwide.
Funding
$1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many promising ophthalmic research projects from small firms never progress to market because large pharmaceutical companies lack the capacity or interest to develop them, leaving patients without new treatments for conditions such as ocular pain and dry eye disease.
Solution
Iacta acts as an intermediary that identifies emerging ophthalmic technologies, such as nano‑encapsulation, and partners with major pharma to advance these candidates into clinically viable eye‑drop or injectable products. The company leverages its R&D expertise to accelerate formulation development, regulatory preparation, and clinical testing, thereby shortening the time from discovery to patient availability. By focusing on large, unmet‑need markets, Iacta creates a pipeline of novel therapies that address prevalent ocular conditions. Its collaborative model enables small innovators to access resources and scale while providing pharma partners with de‑risked, ready‑to‑develop assets.
Target Audience
Primary customers are small ophthalmic research companies seeking development support and large pharmaceutical firms looking for innovative, pre‑validated eye‑care assets.
Features
- Proprietary nano‑encapsulation platform that enhances ocular drug delivery and bioavailability
- End‑to‑end development services covering formulation, preclinical studies, and regulatory strategy
- Strategic partnership framework that connects early‑stage research firms with large pharmaceutical companies
- Portfolio focus on high‑volume therapeutic areas, initially ocular pain and dry eye disease
- In‑house expertise in ophthalmic R&D, clinical development, and market commercialization pathways